EPCAM and neoplasm: These results indicate that CTLs stimulated by EpCAM peptide-pulsed DCs can recognize the EpCAM presented by HepG2 cells in the context of HLA-A2and kill EpCAM positive HepG2 tumor cells (Fig 4).